58 related articles for article (PubMed ID: 34256299)
21. Inter-phenotypic differences in CYP2C9 and CYP2C19 metabolism: Bayesian meta-regression of human population variability in kinetics and application in chemical risk assessment.
Quignot N; Więcek W; Lautz L; Dorne JL; Amzal B
Toxicol Lett; 2021 Feb; 337():111-120. PubMed ID: 33232775
[TBL] [Abstract][Full Text] [Related]
22. Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?
Dorne JL; Walton K; Slob W; Renwick AG
Food Chem Toxicol; 2002 Nov; 40(11):1633-56. PubMed ID: 12176090
[TBL] [Abstract][Full Text] [Related]
23. The Yin-Yang of CYP3A4: a Bayesian meta-analysis to quantify inhibition and induction of CYP3A4 metabolism in humans and refine uncertainty factors for mixture risk assessment.
Quignot N; Wiecek W; Amzal B; Dorne JL
Arch Toxicol; 2019 Jan; 93(1):107-119. PubMed ID: 30298208
[TBL] [Abstract][Full Text] [Related]
24. Association between aripiprazole pharmacokinetics and CYP2D6 phenotypes: A systematic review and meta-analysis.
Zhang X; Xiang Q; Zhao X; Ma L; Cui Y
J Clin Pharm Ther; 2019 Apr; 44(2):163-173. PubMed ID: 30565279
[TBL] [Abstract][Full Text] [Related]
25. Human variability in polymorphic CYP2D6 metabolism: Implications for the risk assessment of chemicals in food and emerging designer drugs.
Darney K; Lautz LS; Béchaux C; Wiecek W; Testai E; Amzal B; Dorne JLCM
Environ Int; 2021 Nov; 156():106760. PubMed ID: 34256299
[TBL] [Abstract][Full Text] [Related]
26. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
[TBL] [Abstract][Full Text] [Related]
27. Human variability in influx and efflux transporters in relation to uncertainty factors for chemical risk assessment.
Darney K; Turco L; Buratti FM; Di Consiglio E; Vichi S; Roudot AC; Béchaux C; Testai E; Dorne JLCM; Lautz LS
Food Chem Toxicol; 2020 Jun; 140():111305. PubMed ID: 32234423
[TBL] [Abstract][Full Text] [Related]
28. Pharmacogenetics and psychopharmacotherapy.
Poolsup N; Li Wan Po A; Knight TL
J Clin Pharm Ther; 2000 Jun; 25(3):197-220. PubMed ID: 10886465
[TBL] [Abstract][Full Text] [Related]
29. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
Zanger UM; Raimundo S; Eichelbaum M
Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):23-37. PubMed ID: 14618296
[TBL] [Abstract][Full Text] [Related]
30. Pharmacogenomics and therapeutic prospects in dementia.
Cacabelos R
Eur Arch Psychiatry Clin Neurosci; 2008 Mar; 258 Suppl 1():28-47. PubMed ID: 18344047
[TBL] [Abstract][Full Text] [Related]
31. Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: a review.
Dorne JL; Walton K; Renwick AG
Food Chem Toxicol; 2005 Feb; 43(2):203-16. PubMed ID: 15621332
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of the cytochrome P450 2C19 genetic polymorphism.
Desta Z; Zhao X; Shin JG; Flockhart DA
Clin Pharmacokinet; 2002; 41(12):913-58. PubMed ID: 12222994
[TBL] [Abstract][Full Text] [Related]
33. Human Variability in Carboxylesterases and carboxylesterase-related Uncertainty Factors for Chemical Risk Assessment.
Di Consiglio E; Darney K; Buratti FM; Turco L; Vichi S; Testai E; Lautz LS; Dorne JLCM
Toxicol Lett; 2021 Oct; 350():162-170. PubMed ID: 34256091
[TBL] [Abstract][Full Text] [Related]
34. The Effect of CYP2D6 Phenotypes on the Pharmacokinetics of Propafenone: A Systematic Review and Meta-Analysis.
Tran QT; Baek IH; Han NY; Yun HY; Chae JW
Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890339
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
